Advanced Filters
noise

Irritable Bowel Syndrome Clinical Trials

A listing of Irritable Bowel Syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 161 clinical trials
S Spyridon Sofos, MD

Clinnova-IBD, a Prospective Cohort of Patients With Inflammatory Bowel Disease (IBD)

This study is part of the Clinnova program. This is a prospective cohort study including patients with IBD recruited at the time of a treatment change. At least 800 participants (recruited in France, Germany and Luxembourg) will be enrolled, of which 100 participants are expected to be recruited in Luxembourg …

18 years of age All Phase N/A
E Elena S Shalukho, MD

Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in healthy volunteers under fasted conditions.

18 - 45 years of age All Phase 1
H Helen Burgess, Ph.D.

IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms

This research study is testing whether changes in sleep timing and morning light treatment may have an impact on symptoms related to inflammatory bowel disease.

18 years of age All Phase N/A

Immunological Characteristics of Preclinical IBD

The purpose of this study is to evaluate disease progression, in terms of development of symptomatic disease and complications associated with IBD (e.g. fistula, abscess, stricture).

18 years of age All Phase N/A
A Ava Hosseini

Efficacy of Rifaximin With NAC in IBS-D

The purpose of this study is to examine the effectiveness of using a combination of a drug, rifaximin and a dietary supplement, N-acetyl-L-cysteine (NAC), to treat patients with irritable bowel syndrome with diarrhea (IBS-D). Rifaximin is one of the standard treatments for IBS-D and is FDA approved. While rifaximin is …

18 years of age All Phase 2
J Julia C Finkel, MD

Therapeutic Endpoint in Pediatric IBD Conditions

The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. …

6 - 21 years of age All Phase N/A

Investigating Serotonin Signalling in IBD Patients

Alterations in normal serotonin (5-hydroxytryptamine;5-HT) signaling have been reported in ulcerative colitis (UC) and Crohn's disease (CD). Studies report an increase in enterochromaffin (EC) cell, main source of 5-HT in the gut, numbers in CD and UC patients. Up-regulated expression of mucosal Tryptophan hydroxylase (TPH)-1, catalytic enzyme in 5-HT production, …

19 - 85 years of age All Phase N/A

Predictors of Prognosis in IBD Patients

A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease

18 years of age All Phase N/A
D David Armstrong, MD

Assessing Interventions of Diet in IBD

In this study, we are trying to learn how certain diets affect people with inflammatory bowel disease (IBD). We want to understand what makes it hard or easy for them to stick to different eating plans, like intermittent fasting, the Mediterranean diet, and the Low FODMAP diet. By finding out …

18 years of age All Phase N/A
S Sarah C Faloon

Nutrition and Clinical Outcomes in IBD

The goal of this observational study is to demonstrate that nutritional status and body composition have an impact on clinical outcomes in inflammatory bowel disease (IBD). The main objectives are: To compare the detection rates of undernutrition between a range of nutritional screening tools, physiological measures and assessment tools amongst …

16 years of age All Phase N/A

Simplify language using AI